Search clinical trials for: HS-10381

Total 213 results

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383

Cough

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383

Cough

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)

Cough
Hansoh BioMedical R&D Company

Not yet recruiting

A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women

Vasomotor Symptoms

China
Hansoh BioMedical R&D Company

Recruiting

Study of HS-10384 in Participants of Chinese Postmenopausal Women

Vasomotor Symptoms

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

CML, Chronic Phase | CML, Accelerated Phase

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-10380 in Chinese Participants

Schizophrenia

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia

Schizophrenia
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 in T2DM Participants

Type 2 Diabetes

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study of HS-10353 in Chinese Participants.

Major Depressive Disorder

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression

Treatment Resistant Depressive Disorder

China
Maxinovel Pty., Ltd.

Recruiting

MAX-10181 in Patients With Advanced Solid Tumor (PD-L1)

Solid Tumor

China
Maxinovel Pty., Ltd.

Recruiting

MAX-10181 Given Orally to Patients With Advanced Solid Tumor

Solid Tumor

Australia
Qingdao Sino-Cell Biomedicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; West China... and other collaborators

Recruiting

HS-IT101 Injection in the Treatment of Advanced Solid Tumors

Solid Tumor

China
Zhejiang Hisun Pharmaceutical Co. Ltd.

Completed

Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia (HS-25-III-01)

Primary Hypercholesterolemia
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction

Healthy

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Phase 1a Study in Healthy Participants

Healthy
Heartseed Inc.

Recruiting

A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study) (LAPiS)

Heart Failure | Ischemic Heart Disease

Japan
Hansoh BioMedical R&D Company

Recruiting

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Psoriasis

China
NuCana plc

Terminated

NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

Ovarian Cancer

United States, United Kingdom
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Trial of HS-10511 in Healthy Subjects

Hypertrophic Cardiomyopathy
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10518 in Healthy Female Participants

Endometriosis
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10517 in Chinese Adult Participants

COVID-19

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10353 in Adult Participants With Major Depressive Disorder

Major Depressive Disorder (MDD)
Imperial College London
Nucana

Completed

NUC-1031 in Patients With Advanced Solid Tumours (ProGem1)

Cancer

United Kingdom
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Overweight and Obesity

China
Nicole Hamblett
University of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...

Completed

Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study (SIMPLIFY-HS)

Cystic Fibrosis

United States
Heat Biologics

Completed

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

Advanced Solid Tumor

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 in Healthy Participants

Type 2 Diabetes

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Psoriasis

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostatic Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Herbert Lyerly

Terminated

A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies

Solid Tumor

United States
HeadSense Medical
Rigshospitalet, Denmark

Unknown

Comparison of the Non-invasive ICP HeadSense Monitor vs Lumbar CSF Pressure Measurement

Intracranial Hypertension

Denmark, Germany, Netherlands
HeadSense Medical
State Medical Center, Republic of Armenia

Completed

An Evaluation of Non-invasive ICP Monitoring in Patients Undergoing Routine Care

Stroke

Armenia
Shanghai Hansoh Biomedical Co., Ltd

Recruiting

A Study of HS-20089 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma
Hansoh BioMedical R&D Company

Recruiting

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Sarcoma | Osteosarcoma

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Advanced Non-Small-Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors

Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study of HS-10342 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Atridia Pty Ltd.

Completed

A Phase I Trial of HS-10241 in Solid Tumors

Solid Tumors | Neoplasm

Australia
Universitätsmedizin Mannheim

Withdrawn

HS-PCI in Locally Advanced Adenocarcinoma of the Lung (HIPPO-S)

Adenocarcinoma | Lung Cancer | Lymphatic Metastasis
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours

Carcinoma | Solid Tumor, Adult

China
HeadSense Medical
Oslo University Hospital

Completed

Development and Evaluation of the ICP Waveform Tracing Capabilities and Safety of HS-1000 Device

Brain Injuries | Intracranial Hypertension

Norway
Baohui Han
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns (APPOINT)

Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers

Healthy

China

Search clinical trials for: HS-10381

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations